Management of Metastatic Pancreatic Cancer-Comparison of Global Guidelines over the Last 5 Years.

Autor: Pajewska M; Department of Health Economics and Medical Law, Medical University of Warsaw, 01-445 Warsaw, Poland.; Department of Economic and System Analyses, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland., Partyka O; Department of Health Economics and Medical Law, Medical University of Warsaw, 01-445 Warsaw, Poland.; Department of Economic and System Analyses, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland., Czerw A; Department of Health Economics and Medical Law, Medical University of Warsaw, 01-445 Warsaw, Poland.; Department of Economic and System Analyses, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland., Deptała A; Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland., Cipora E; Medical Institute, Jan Grodek State University in Sanok, 38-500 Sanok, Poland., Gąska I; Medical Institute, Jan Grodek State University in Sanok, 38-500 Sanok, Poland., Wojtaszek M; Medical Institute, Jan Grodek State University in Sanok, 38-500 Sanok, Poland., Sygit K; Faculty of Health Sciences, Calisia University, 62-800 Kalisz, Poland., Sygit M; Faculty of Health Sciences, Calisia University, 62-800 Kalisz, Poland., Krzych-Fałta E; Department of Basic of Nursing, Faculty of Health Sciences, Medical University of Warsaw, 01-445 Warsaw, Poland., Schneider-Matyka D; Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland., Cybulska AM; Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland., Grochans E; Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland., Asendrych-Woźniak A; Clinical Department of Oncology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warsaw, Poland., Romanowicz A; Clinical Department of Oncology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warsaw, Poland., Drobnik J; Department of Family Medicine, Faculty of Medicine, Wroclaw Medical University, 51-141 Wroclaw, Poland., Bandurska E; Center for Competence Development, Integrated Care and e-Health, Medical University of Gdansk, 80-204 Gdansk, Poland., Ciećko W; Center for Competence Development, Integrated Care and e-Health, Medical University of Gdansk, 80-204 Gdansk, Poland., Maciuszek-Bartkowska B; Department of Biophysics, Poznan University of Medical Sciencies, 60-780 Poznan, Poland., Curyło M; Department of Internal Medicine, Rehabilitation and Physical Medicine, Medical University of Lodz, 90-647 Lodz, Poland.; Medical Rehabilitation Department, The Ministry of the Interior and Administration Hospital, 30-053 Cracow, Poland., Wróbel K; Department of Management and Logistics in Healthcare, Medical University of Lodz, 90-131 Lodz, Poland., Kozłowski R; Center for Security Technologies in Logistics, Faculty of Management, University of Lodz, 90-237 Lodz, Poland., Marczak M; Collegium of Management, WSB Merito University in Warsaw, 03-204 Warszawa, Poland.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Sep 02; Vol. 15 (17). Date of Electronic Publication: 2023 Sep 02.
DOI: 10.3390/cancers15174400
Abstrakt: Pancreatic cancer (PC) is usually diagnosed at an advanced stage of its development, which results in lower overall survival (OS). Prognosis is also poor even with curative-intent surgery. Approximately 80% of patients with localized PDAC have micrometastases at the time of diagnosis, which leads to a worse prognosis than in other cancers. The objective of this study is to present the progress in the treatment of metastatic pancreatic cancer based on the recommendations of oncological scientific societies, such as ESMO, NCCN, ASCO, NICE and SEOM, over the last 5 years. Combined FOLFIRINOX therapy is mostly a recommended therapy among patients with good performance statuses, while gemcitabine is recommended for more fragile patients as a first-line treatment. The newest guidelines suggest that molecular profiling of the tumor should be the first step in determining the course of treatment. The use of modern molecular therapies in patients with specific gene mutations should extend the survival of patients with this disease.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje